House & Home
Wed, March 23, 2011Tue, March 22, 2011Mon, March 21, 2011Sat, March 19, 2011Fri, March 18, 2011Thu, March 17, 2011Wed, March 16, 2011Tue, March 15, 2011Mon, March 14, 2011Fri, March 11, 2011Thu, March 10, 2011Wed, March 9, 2011Tue, March 8, 2011Mon, March 7, 2011Sun, March 6, 2011Sat, March 5, 2011Fri, March 4, 2011Thu, March 3, 2011Wed, March 2, 2011Tue, March 1, 2011Mon, February 28, 2011Sun, February 27, 2011Fri, February 25, 2011Thu, February 24, 2011Wed, February 23, 2011Tue, February 22, 2011Mon, February 21, 2011Fri, February 18, 2011Thu, February 17, 2011Wed, February 16, 2011Tue, February 15, 2011Mon, February 14, 2011Sun, February 13, 2011Fri, February 11, 2011Thu, February 10, 2011CNS Response Announces Collaborative Agreement With Medco to Assess Impact of Referenced-EEG(R)
//house-home.news-articles.net/content/2011/03/0 .. -medco-to-assess-impact-of-referenced-eeg-r.html
Published in House and Home on Tuesday, March 1st 2011 at 7:45 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
ALISO VIEJO, CA--(Marketwire - March 1, 2011) - CNS Response, Inc. (
"Our collaborative agreement with Medco provides another opportunity for an outside, third party to assess the benefits of rEEG as an information tool to assist physicians in treating patients with mental health issues," said Mike Darkoch, executive vice president of CNS Response. "This project will include a pharmaco-economic study of rEEG patients over the past ten years, many of whom received medications dispensed by Medco."
"Trial and error pharmacotherapy has become the dominant treatment model for people who have failed on two or more medications, with enormous implications for healthcare costs," said CNS Response CEO George Carpenter. "While medical professionals already indicate that our reports help them reduce trial and error, we expect the depth of Medco's data resources and analytic expertise to yield additional insights on the efficacy of rEEG from a clinical and economic perspective."
Developed by CNS Response, rEEG is an online reference database that offers medical professionals objective, personalized statistical data on their patients' neurophysiology. While most physicians in other disciplines are able to base their treatment decisions on objective data gathered from EKGs, MRIs, blood tests and similar procedures, such advances have not previously been available to medical professionals treating mental illness. The data provided by CNS Response enables medical professionals to better understand an individual patient's neurophysiology, thereby reducing medication trial and error.
In a recent study published by the Journal of Psychiatric Research, physicians who used rEEG achieved a 65 percent success rate in treating patients with depression, compared to a 39 percent success rate with the control group. Those results were even more significant because the subjects in the study, selected through a randomized process, had failed an average of four previous treatments for depression. The Journal of Psychiatric Research study article can be found online at [ www.cnsresponse.com ].
About CNS Response
CNS Response provides reference data and analytic tools for clinicians and researchers, using a novel neurometric database called Referenced-EEG® (rEEG). Developed by physicians as a platform to exchange objective, neurophysiology-based data on medication response and outcomes, physicians using rEEG in clinical trials have consistently reduced their use of trial and error pharmacotherapy. To read more about the benefits of this patented technology for patients, physicians and payers, please visit the CNS Response website, [ www.cnsresponse.com ].
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.